NCT00851435View on ClinicalTrials.gov

Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
PneumoniaVentilator Associated Pneumonia
Interventions
BIOLOGICAL

KBPA-101

1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day

Trial Locations (1)

Unknown

Several sites in Switzerland, France, Belgium and Greece, Basel

Sponsors

Lead Sponsor

Kenta Biotech Ltd
All Listed Sponsors
lead

Kenta Biotech Ltd

INDUSTRY